Lithium medication protects against suicide

[PRESS RELEASE 2017-06-09] Suicidal behaviour decreases among individuals with bipolar disorder during periods of lithium medication, according to an extensive register-based study conducted at Karolinska Institutet in Sweden. The results are published in The American Journal of Psychiatry.

More than one percent of the world’s population is affected by bipolar disorder. The disease is characterised by alternating periods of depression and elevated mood (mania). Medication with lithium and valproate prevents manic phases and has mood-stabilizing effects. It is known that people with bipolar disorder have a high risk of committing suicide, but whether the drugs reduce the risk of suicide has not been sufficiently investigated. Researchers at Karolinska Institutet have, therefore, conducted an extensive register-based study. 

”We now strongly augment the existing evidence that lithium treatment is protective against suicide attempts and suicide”, says Professor Paul Lichtenstein at Karolinska Institutet’s Department of Medical Epidemiology and Biostatistics. ”We estimate that more than ten per cent of attempted or completed suicides could have been avoided if these individuals had been continuously taking lithium during the study period”. 

The study was performed in collaboration with the University of Gothenburg and included more than 51,000 individuals with bipolar disorder from the Swedish National Patient Registry over an eight-year period (2006-2013). During this period, 10,648 suicide-related events occurred. All participants in the study were compared to themselves during periods with and without medication with lithium and valproate, respectively. The risk of suicide-related events was reduced by 14 per cent while individuals were receiving lithium, as compared with the same individuals while not receiving lithium. 

The study also demonstrates that valproate, the most common alternative to lithium, probably has no effect on suicidal behaviour. Lithium medication has decreased steadily in recent years in Sweden. Paul Lichtenstein believes that the results of the study are of relevance for clinical decisions. 

”When a doctor is trying to find the best pharmacological treatment for the patient, the anti-suicidal effect of lithium should be taken into consideration, especially for patients with suspected suicidal intentions”, says Paul Lichtenstein. 

The study was financed with grants from the Swedish Research Council, the Swedish Council for Working Life and Social Research, the Swedish foundation for Strategic Research, and the China Scholarship Council. No commercial interests have been reported.

Publication: ‘Suicidal Behavior During Lithium and Valproate Medication: A Within-individual Eight Year Prospective Study of 50,000 Patients With Bipolar Disorder’. Jie Song, Arvid Sjölander, Erik Joas, Sarah E. Bergen, Bo Runeson, Henrik Larsson, Mikael Landén, Paul Lichtenstein. The American Journal of Psychiatry, online 9 June 2017.

For more information, please contact:
Mikael Landén, Professor 
Department of Medical Epidemiology and Biostatistics, Karolinska Institutet 
Institute of Neuroscience and Physiology at Sahlgrenska Academy, University of Gothenburg 
Phone: +46 (0)702 08 23 04
E-mail: or 

Karolinska Institutet is one of the world’s leading medical universities. Its vision is to significantly contribute to the improvement of human health. Karolinska Institutet accounts for the single largest share of all academic medical research conducted in Sweden and offers the country’s broadest range of education in medicine and health sciences. The Nobel Assembly at Karolinska Institutet selects the Nobel laureates in Physiology or Medicine.


About Us

KAROLINSKA INSTITUTET PRESS OFFICE Opening hours: Monday–Friday 8–20 CET, weekends 9–17 CET Karolinska Institutet – a medical university